Lisata Terminates Qilu Licensing Agreement, Regains Rights to Pancreatic Cancer Drug

Lisata Therapeutics has terminated a licensing agreement with Qilu Pharmaceutical for its cancer drug candidate certepetide in the Greater China region. Lisata will regain full rights to the drug, while Qilu will remain responsible for completing a Phase 2 clinical trial. Lisata will negotiate with Qilu on the potential licensing of the trial data.